James Mullen - Editas Medicine Chairman of the Board
| EDIT Stock | USD 2.37 0.04 1.66% |
Chairman
Mr. James C. Mullen is Independent Chairman of the Board of the Board of the Company. Mr. Mullen previously served as Chief Executive Officer and a director of Patheon N.V., a pharmaceutical contract development and manufacturing organization, from March 2011 until its acquisition by Thermo Fisher Scientific, Inc., a public biotechnology product development company, in August 2017. Prior to joining Patheon, from June 2000 to June 2010, Mr. Mullen served as the president and chief executive officer of Biogen Inc., one of the world largest biotechnology companies. Mr. Mullen held various operating positions at Biogen prior to becoming Chief Executive Officer, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Prior to joining Biogen, Mr. Mullen held several manufacturing and engineering positions at SmithKline Beecham . Mr. Mullen has served on the board of directors of Thermo Fisher since November 2018 and as the executive chairman of the board of Vicarius Pharma AG, a private biopharmaceutical commercialization company, since August 2017. Mr. Mullen previously served on the board of directors of Insulet from September 2017 until January 2019 and PerkinElmer, Inc., a public technology and service provider for diagnostics, research, environmental and industrial and laboratory services markets, from 2003 to April 2015. He also previously served as Chairman of the Biotechnology Innovation Organization since 2018.
| Age | 65 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 11 Hurley Street, Cambridge, MA, United States, 02141 |
| Phone | 617 401 9000 |
| Web | https://www.editasmedicine.com |
Editas Medicine Management Efficiency
The company has return on total asset (ROA) of (0.3432) % which means that it has lost $0.3432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7856) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| MD FACS | Allogene Therapeutics | 75 | |
| Jeffrey MD | Vertex Pharmaceuticals | 68 | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 |
Editas Medicine Leadership Team
Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilmore MD, CEO President | ||
| Bruce Eaton, Exec Officer | ||
| Gilmore ONeill, CEO President | ||
| Cristi Barnett, Corporate Relations | ||
| Charlene JD, Executive Counsel | ||
| James Mullen, Chairman of the Board | ||
| Michelle Robertson, Principal CFO | ||
| David Liu, CoFounder Member | ||
| Caren Deardorf, Executive Officer | ||
| Pr Church, CoFounder Member | ||
| Harry III, VP Operations | ||
| Mark Shearman, Ex Officer | ||
| Feng Zhang, CoFounder Member | ||
| Baisong MD, Executive Officer | ||
| Linea Aspesi, Executive Officer | ||
| Linda Burkly, Executive Officer | ||
| CPA CFA, CFO VP | ||
| George Church, CoFounder Member | ||
| Gregory Whitehead, Executive Officer |
Editas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (30.96 M) | ||||
| Shares Outstanding | 82.55 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 70.11 % | ||||
| Number Of Shares Shorted | 17.24 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 3.17 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.